Loading clinical trials...

A Multicenter Breast Cancer Biospecimen Registry | Clinical Trials | Clareo Health

UNKNOWN

A Multicenter Breast Cancer Biospecimen Registry

NCT02712645•Luminist, Inc.

Summary

This study is being performed to collect blood for the development of noninvasive tests that can screen for or diagnose cancer. Blood samples will be collected from women who are scheduled to have breast biopsies.

Eligibility

Age

40 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Females of all racial and ethnic groups who are 40 years or older.
•2. Women must:
•1. have suspected neoplasm of the breast (BIRADS 4 or 5) based on the results of any breast screening or diagnostic imaging, such as mammogram, and
•2. be selected or scheduled for a breast biopsy which has not yet been conducted at the time of enrollment.

Exclusion Criteria

•1. Inability to sign informed consent.
•2. More than one radiological finding.
•3. Any current or prior cancer (with the exception of non-melanoma skin cancer or a suspected breast malignancy targeted for biopsy).
•4. Any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days.
•5. Any surgery, hospitalization, or institutionalization (such as in a nursing home) during the previous 3 months.
•6. Received any experimental therapeutic treatment during the previous 3 months.
•7. Received any blood product transfusion within the previous 3 months.
•8. Use of illegal drugs during the previous 3 months.
•9. Pregnant or nursing at the time of enrollment or in the preceding 12 months.

Locations (2)

Redding, California, United States

Dallas, Texas, United States

Key Dates

Start Date

February 1, 2016

Primary Completion Date

December 1, 2017

Last Updated

April 6, 2016

Enrollment

700

ESTIMATED participants

Conditions

Breast Cancer

Contacts

Storm Stillman

CONTACT

clinical@luminist.io

Will Olsen

CONTACT

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGNA

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Multicenter Breast Cancer Biospecimen Registry

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer